Podcasts about nhs

Daniel Mahncke and Shawn O'Malley take a deep dive into Palantir (NASDAQ: PLTR), the data and AI platform behind everything from battlefield targeting systems to Airbus's A350 production line, with customers including the U.S. Army, the NHS, Ferrari, and Airbus. Palantir is growing revenue at over 90%, with net dollar retention at 157% and adjusted operating margins above 60% — a Rule of 40 score of 155%, roughly double what the best software companies in the world achieve. It also trades at around 60 times sales, which is why The Economist called it possibly the most overvalued firm of all time. Daniel and Shawn discuss whether the ontology layer is a sustainable moat now that Microsoft and Google have launched competing products, what Alex Karp and Peter Thiel's politics mean for a company selling to Western governments, and why twenty years of losses turned into the fastest-accelerating software business on the market. In the end, Daniel values the business and decides whether PLTR deserves a spot in The Intrinsic Value Portfolio. IN THIS EPISODE YOU'LL LEARN: (00:00:00) Intro (00:02:29) How Palantir's Ontology actually works (00:16:26) How AI turned around Palantir's business (00:20:59) Why Palantir has the best margins in the industry (00:34:22) Why no one seems to be able to copy Palantir's Ontology (00:38:01) How Palantir grows its customer base (01:07:36) Palantir's valuation discussion (01:11:37) How much Palantir stock is actually worth (01:12:52) Whether PLTR will be added to The Intrinsic Value Portfolio Disclaimer: Slight discrepancies in the timestamps may occur due to podcast platform differences. BOOKS AND RESOURCES Join the exclusive ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Intrinsic Value Mastermind Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Track ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Intrinsic Value Portfolio⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Learn more about how to join us in NYC for our ⁠⁠⁠⁠⁠⁠⁠Intrinsic Value Conference⁠⁠⁠⁠⁠⁠⁠. Portfolio Review ⁠⁠⁠⁠⁠⁠Submit Tool⁠⁠⁠⁠⁠⁠. Satish Terala's ⁠AI Masterclass⁠. Future Investing's ⁠Interview with a Palantir FDE.⁠ Check out our previous Intrinsic Value breakdowns: ⁠Constellation Software⁠, ⁠Dell⁠, ⁠Alphabet⁠, ⁠Constellation Software Spinoffs⁠. Related ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠books⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ mentioned in the podcast. Ad-free episodes on our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Premium Feed⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. NEW TO THE SHOW? Get smarter about valuing businesses through ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Intrinsic Value Newsletter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Check out ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Investor's Podcast Starter Packs⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Follow our official social media accounts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠X⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Try our tool for picking stock winners and managing our portfolios: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TIP Finance⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Enjoy exclusive perks from our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠favorite Apps and Services⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Learn how to better start, manage, and grow your business with the ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠best business podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. SPONSORS Support our free podcast by supporting our sponsors: Fiscal.AI References to any third-party products, services, or advertisers do not constitute endorsements, and The Investor's Podcast Network is not responsible for any claims made by them. Support our show by becoming a premium member! https://theinvestorspodcastnetwork.supportingcast.fm

Today, NHS bosses have warned of chaos in ADHD and autism care as costs spiral and unregulated private providers capitalise on the huge demand for help.Health editor Hugh Pym is in the studio to describe what's been going on in the NHS, and why bosses are warning about what's going on behind the scenes as requests for ADHD and autism diagnoses rise.And, what more have we learned about the unannounced visit of CIA chief John Ratcliffe to Moscow earlier this week? The Economist's Washington bureau chief Shashank Joshi unpacks the reports around possible motives for his visit, including warning Russia against attacking NATO members. Plus, as the war in Iran enters its sixth month - what is the mood around President Trump? You can now listen to Newscast on a smart speaker. If you want to listen, just say "Ask BBC Sounds to play Newscast”. It works on most smart speakers. You can join our Newscast online community here: https://bbc.in/newscastdiscordGet in touch with Newscast by emailing newscast@bbc.co.uk or send us a WhatsApp on +44 0330 123 9480.New episodes released every day. If you're in the UK, for more News and Current Affairs podcasts from the BBC, listen on BBC Sounds: https://bbc.in/4guXgXd Newscast brings you daily analysis of the latest political news stories from the BBC. The presenter was Adam Fleming. It was made by Jack Maclaren with Eleanor Harrison-Dengate. The social producer was Joe Wilkinson. The technical producer was Mike Regaard. The assistant editor is Chris Gray. The senior news editor is Sam Bonham.

Daniel Mahncke and Shawn O'Malley take a deep dive into Palantir (NASDAQ: PLTR), the data and AI platform behind everything from battlefield targeting systems to Airbus's A350 production line, with customers including the U.S. Army, the NHS, Ferrari, and Airbus. Palantir is growing revenue at over 90%, with net dollar retention at 157% and adjusted operating margins above 60% — a Rule of 40 score of 155%, roughly double what the best software companies in the world achieve. It also trades at around 60 times sales, which is why The Economist called it possibly the most overvalued firm of all time. Daniel and Shawn discuss whether the ontology layer is a sustainable moat now that Microsoft and Google have launched competing products, what Alex Karp and Peter Thiel's politics mean for a company selling to Western governments, and why twenty years of losses turned into the fastest-accelerating software business on the market. In the end, Daniel values the business and decides whether PLTR deserves a spot in The Intrinsic Value Portfolio. IN THIS EPISODE YOU'LL LEARN: (00:00:00) Intro (00:02:29) How Palantir's Ontology actually works (00:16:26) How AI turned around Palantir's business (00:20:59) Why Palantir has the best margins in the industry (00:34:22) Why no one seems to be able to copy Palantir's Ontology (00:38:01) How Palantir grows its customer base (01:07:36) Palantir's valuation discussion (01:11:37) How much Palantir stock is actually worth (01:12:52) Whether PLTR will be added to The Intrinsic Value Portfolio Disclaimer: Slight discrepancies in the timestamps may occur due to podcast platform differences. BOOKS AND RESOURCES Join the exclusive ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Intrinsic Value Mastermind Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Track ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Intrinsic Value Portfolio⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Learn more about how to join us in NYC for our ⁠⁠⁠⁠⁠⁠Intrinsic Value Conference⁠⁠⁠⁠⁠⁠. Portfolio Review ⁠⁠⁠⁠⁠Submit Tool⁠⁠⁠⁠⁠. Satish Terala's AI Masterclass. Future Investing's Interview with a Palantir FDE. Check out our previous Intrinsic Value breakdowns: Constellation Software, Dell, Alphabet, Constellation Software Spinoffs. Related ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠books⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ mentioned in the podcast. Ad-free episodes on our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Premium Feed⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. NEW TO THE SHOW? Get smarter about valuing businesses through ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Intrinsic Value Newsletter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Check out ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Investor's Podcast Starter Packs⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Follow our official social media accounts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠X⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Try our tool for picking stock winners and managing our portfolios: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TIP Finance⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Enjoy exclusive perks from our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠favorite Apps and Services⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Learn how to better start, manage, and grow your business with the ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠best business podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. SPONSORS Support our free podcast by supporting our ⁠⁠⁠⁠⁠⁠sponsors⁠⁠⁠⁠⁠⁠: Scribe Plus500 Netsuite Plaud References to any third-party products, services, or advertisers do not constitute endorsements, and The Investor's Podcast Network is not responsible for any claims made by them. Support our show by becoming a premium member! https://theinvestorspodcastnetwork.supportingcast.fm

People who were sexually abused as children and later seek help for mental health problems are being failed by the NHS, according to The Royal College of Psychiatrists. The RCOP has issued a public apology, saying decades of mismanagement and misdiagnosis have left many survivors without the support they need. Anita Rani is joined by Caroline Thompson, a survivor of childhood sexual abuse, and Dr Jo Stubley, a consultant psychiatrist and clinical lead of the Tavistock Trauma Service, who are co-authors of the RCOP's position statement. Today in towns and cities across the country, parents are being encouraged to go on strike to raise awareness about, what the strike's organisers say are the rising costs of raising children and the impossible demands this puts on parents. Anna Whitehouse, the founder of Flex Appeal, and George Gabriel, who co-founded The Dad Shift, discuss the flexible working and parental leave policies that they are calling for with The Parent Strike and how the Government is responding. For more than a decade, armed gangs in northern Nigeria have repeatedly targeted schools, kidnapping children for ransom and forcing some educational establishments to close. BBC journalist Yemisi Adegoke has recently returned from the state of Zamfara, where ongoing insecurity has left many girls unable to attend school, threatening their futures.Bella Mackie's third novel, Claws Out!, is published this week. It's a witty crime caper about an ageing ‘gold-digger,' who is rumoured to have murdered three husbands and has a new suitor in sight. Bella - whose debut How to Kill Your Family is currently being turned into a Netflix series starring Anya Taylor-Joy - tells Anita why she loves exploring the British class system in her books and why she's determined to use her platform to talk openly about mental health.Presenter: Anita Rani Producer: Rebecca Myatt

Could allowing patients to choose their own appointment times help reduce missed visits and shorten NHS waiting lists? In this episode of Tech Talks Daily, I speak with Alison MacDonald, European Lead and Senior Vice President at Nordic Global. Alison brings an unusual combination of clinical and technology experience as a registered nurse who moved into digital health over 15 years ago. Her career began in community nursing, where she was asked to lead an electronic health record project because colleagues thought she was good with computers. What initially appeared to be a simple exercise in converting paper forms into digital records encouraged her to question whether healthcare could redesign the process rather than copy it onto a screen. We discuss Nordic's work with Cambridge University Hospitals NHS Foundation Trust on patient self-scheduling and automated earlier appointment offers. Before the program, missed outpatient appointments were removing valuable clinical capacity while administrative teams spent time calling patients and rearranging bookings. Cambridge introduced self-scheduling through Epic MyChart, allowing patients to select appointment times through the patient portal. Alison says the DNA rate fell from 5% to 2.2% during the program. According to the supplied results, over 20,000 patients successfully scheduled their own appointments and over 3,000 accepted offers to attend earlier when cancellations created availability. Patients moved appointments forward by an average of 16 days. Forty percent of accepted earlier appointments occurred within seven days of the offer, while 7% took place on the same or following day. Administrative teams also saved an estimated ten minutes for every self-booked appointment. Alison explains why patient control can improve attendance. People can choose times that work around employment, caring responsibilities, travel, and family life instead of receiving a fixed appointment through a letter or telephone call. Patients can also cancel or reschedule without waiting for somebody to answer the phone. The operational lesson goes beyond appointment booking. Healthcare systems may be able to recover existing capacity by examining missed appointments, theater scheduling, waiting list processes, pre-visit questionnaires, and patient communications before concluding that every problem requires additional staff or facilities. We also discuss where AI is producing practical results in healthcare. Alison points to medical imaging, emergency department triage, waiting list management, clinical documentation, and workforce deployment. She warns against discussing AI as one generic solution because each application requires a defined use case, suitable data, workable processes, governance, and staff adoption. Ambient clinical documentation offers one example. An AI scribe can record a consultation, prepare a structured note, and pass it to the clinician for review and correction. Alison cites an NHS evaluation reporting a 23.5% increase in direct patient interaction time and an 8.2% reduction in appointment length. Interoperability remains another major challenge. Healthcare journeys cross hospitals, primary care, community services, and specialist providers that may use different systems or a mixture of electronic and paper records. Even basic differences, such as one organization measuring pain on a five-point scale and another using ten points, can prevent reliable comparison. Alison recommends agreeing on common data standards, defining the minimum patient information required during care transitions, including interoperability requirements in procurement, and avoiding bespoke integrations that make future information sharing harder. Digital access also requires balance. Online services can improve convenience, but healthcare providers must retain appropriate alternatives for patients who lack digital skills, connectivity, confidence, or access. Could your healthcare organization improve patient access and staff capacity by redesigning one familiar process before purchasing another large technology platform? Listen to the episode and share your thoughts with me.

Women who have missed a cervical screening appointment in England are to be offered HPV self-testing kits by the NHS. Over the next year, nearly four million women will receive invites on the NHS App or via text message, email or letter to order a free kit to use at home. The aim is to encourage more women to complete their potentially lifesaving screening to detect HPV, which can increase the risk of cervical cancer. Figures show that around a third of women who are eligible for cervical cancer screening have not taken up the offer recently. Dr Sue Mann, National Clinical Director for Women's Health in England and a consultant in Sexual and Reproductive Health, joins Nuala McGovern to discuss.Chef Sally Abe, who owns the restaurant The Pem, and Kayla Lawrie, a producer with social media food influencers TopJaw, have launched a map of women-owned hospitality businesses. What began with 350 restaurants, pubs, cafés and bakeries has now grown to more than 1,000 venues across the UK. They explain to Nuala what they hope to achieve.Around 7,500 women are diagnosed with ovarian cancer every year, with the majority aged over 50. But around 120 of those women are between 15 and 24. Enlli Thompson was just 19 when a growth was found on one of her ovaries. Since then, she's undergone chemotherapy, egg freezing, a hysterectomy and medically induced menopause. Enlli joins Nuala, alongside GP Charlotte Badescu, who was also diagnosed with ovarian cancer in 2021 when she was 31.Stephanie Brown from the University of Hull has spent the past year as Woman's Hour's researcher in residence on the scheme that Radio 4 runs with the Arts and Humanities Research Council. She studies the history of crime and, as part of our summer series exploring some of the latest research into women's lives past and present, she shares new findings about the punishment of women in medieval England.Is your wardrobe a clutter-free haven of beautifully coordinated outfits? Or is it more a chaotic jumble of jumpers, jeans and everything in between? Could an app be the answer? Some apps allow users to catalogue what they own, visualise outfits and experiment with their style. Nuala is joined by Nicole Glennon, Deputy Editor of the Irish Examiner Weekend magazine, and Dion Terrelonge, fashion psychologist and practitioner.Presenter: Nuala McGovern Producer: Dianne McGregor

Send me a DM here (it doesn't let me respond), OR email me: imagineabetterworld2020@gmail.comIn this 2014 segment from the Bases 37 interviews (conducted by Miles Johnston in Broadstairs, Kent), Max Spiers discusses alleged occult and programming elements within the music industry.  He connects pop music and celebrity culture to bloodline rituals, referencing Aleister Crowley's unfinished work at Boleskine House, the 72 demons associated with King Solomon, energy grids, and portals. Spiers claims the industry harvests individuals from specific bloodlines for ritual purposes, citing examples involving Bob Geldof, the death of Peaches Geldof, and Michael Hutchence. He references James Casbolt's list of “endangered” people and links these themes to broader claims of satanic networks, Live Aid symbolism, NHS tracking, and Project Oak Tree.  The conversation also covers reptilian/inner-earth influences (including the Rothschild family as intermediaries), the Black Sun, Montauk-related time travel, crystal skulls, reincarnation cycles tied to the precession of the equinoxes, and Spiers' own reported super-soldier experiences (implants, DNA aspects, and early trauma). The interviewer interjects frequently. The segment ends with comments on shifting planetary forces and a possible reset.  This is one extracted portion of the larger multi-part Bases 37 series.

Dr Hazel Wallace joins Georgie to explore why female physiology still isn't properly accounted for in health, nutrition and performance.Hazel is a former NHS doctor, nutritionist, personal trainer, bestselling author and founder of The Food Medic. She explains how women have historically been treated as “small men” in medical research, and why that can have serious consequences, from misdiagnosis and adverse drug reactions to gaps in our understanding of hormones, nutrition and performance.They discuss how the menstrual cycle can influence energy, motivation, sleep and recovery, why Hazel prefers women to be “cycle aware” rather than rigidly training around different phases, and the nutritional issues that disproportionately affect women, including iron deficiency.The conversation also covers perimenopause, HRT, fertility, IVF and egg freezing, including why the months before conception or egg collection can be important from a nutritional perspective.Plus, she shares the exercise she believes matters most for longevity, the supplement she recommends for many people in the UK, and the one principle she believes every woman should remember:Just because something is common doesn't make it normal.FAQsWho is Dr Hazel Wallace?Dr Hazel Wallace is a former NHS medical doctor, nutritionist, personal trainer, bestselling author and founder of The Food Medic, an educational platform focused on evidence-based health and nutrition.How does the menstrual cycle affect performance?Hazel explains that changing hormone levels can influence factors including energy, motivation, mood, sleep and recovery. However, she says the research does not currently support rigid week-by-week training prescriptions for every woman.Should women train according to their menstrual cycle?Hazel recommends being cycle aware rather than strictly “cycle syncing”. Tracking your own symptoms and recognising when you personally feel strongest or most fatigued can help inform training decisions.Why is iron deficiency particularly relevant for women?Women lose iron through menstruation and can have increased requirements during stages such as pregnancy and breastfeeding. Hazel says iron deficiency is an important issue in female health and performance.Can nutrition affect IVF and egg freezing?Hazel discusses evidence suggesting nutrition can influence fertility-related outcomes and highlights the importance of the period leading up to conception, IVF or egg collection.What does Hazel say about perimenopause?Perimenopause can last months or years and may involve changes in periods, sleep, mood, concentration, hair, skin and temperature regulation. Hazel recommends tracking symptoms and speaking to a healthcare professional if they become troublesome.Does Hazel recommend HRT?Hazel explains that HRT can be safe and effective for many women but is still a medication and isn't appropriate for everybody. Decisions should be made with a doctor based on individual symptoms, risks and medical history.Does Hazel recommend continuous glucose monitors?Not routinely for healthy people. She says unnecessary glucose monitoring can sometimes create anxiety or food obsession.What is the best exercise for longevity?Hazel highlights resistance training, while also stressing that the best form of exercise is ultimately one you can consistently maintain.The Performance People podcast is produced in partnership with J.P. Morgan Private Bank.______Connect with Performance PeopleHit subscribe today for the latest.

Host Dr Russell Thackeray interviews Dale Atkinson from near Reading, a former finance compliance consultant who now works as a patient advocate, audits companies for “patient trust leaks,” sells adjunct wellness modalities, and writes.Dale recounts that in 2024 his partner was diagnosed with small cell lung cancer and surgically cured, then he was found to have a large esophageal tumour and later told he had terminal, metastatic cancer (T4b N3 M1) with 11.5 months to live, after years of GP visits for GI symptoms and a long wait for a “routine” endoscopy.He pursued chemotherapy and immunotherapy alongside extensive research, next-generation sequencing, off-label medications, nutrition/naturopathic support, and modalities such as hyperbaric oxygen, high-dose vitamin C protocols, ketosis/fasting, and medical cannabis, while warning against social-media “snake oil.”He reports no visible signs of disease, has made major lifestyle changes to reduce stress, and is launching a charity, Beyond the Standard, to push NHS change; he emphasises self-advocacy.00:00 Welcome and Introductions00:28 From Finance to Advocacy01:34 A Shocking Cancer Cascade03:38 Years of Missed Symptoms06:09 Turning Anger Into Research09:24 Snake Oil and Red Herrings11:57 Chemo Immuno and Realistic Goals13:17 Next-Gen Sequencing Explained16:41 Integrative Care vs NHS Pathway18:30 Lifestyle Overhaul After Diagnosis20:03 Where to Start Without Rabbit Holes20:41 Avoid Social Media Gurus21:26 Find Credible Integrative Experts22:08 Vetting Doctors and Directories24:27 Biohacking Hype and Supplement Scams25:30 Bloodwork Guided Supplementation26:31 Ketosis and Fasting Strategy28:23 Medical Cannabis for Symptoms31:31 Access and NHS Change Efforts33:51 Prognosis and Staying on Protocol34:37 Hyperbaric Oxygen and Red Light36:43 Self Advocacy and Final TakeawaysYou can contact us at info@qedod.comResources can be found online or link to our website https://resilienceunravelled.com

There are meetings happening in your organisation that you are not in. They take place in corridors, car parks, over lunch and in WhatsApp groups you do not know exist. In these conversations you would find out exactly what the staff think of the culture you have shaped and environment in which they work. Most leaders believe they have created psychological safety but the research shows there is usually a gap between the leaders perception and the reality their staff experience. In this episode James Rule explores that gap, asks the uncomfortable questions every leader should ask themselves to identify it and shares the key step every leader can take to establish psychological safety.KEY TAKEAWAYSWhy the warning signs of a lack of psychological safety have become largely invisible in hybrid and remote working environments. Three practical tests for a leader to establish if psychological safety truly exists in their team.The single most powerful thing you can do to truly establish psychological safety in your culture. Accelerate your growth and development with The Lonely Leader Academy If you want to work through some of these areas in more depth, to accelerate your learning and access tools, tactics and tips to drive performance and enhance fulfilment then check out The Lonely Leader Academy: https://tll.academy/RELATED EPISODES FROM THE ARCHIVEEpisode 22 - Creating psychological safety in a teamEpisode 35 - Leading a Hybrid TeamEpisode 12 - Eight Steps to a Quality CultureENJOYED THE EPISODE?James works with senior leaders, CEOs, and founders who want to perform at the highest level without losing what matters most in the process. If this conversation has prompted something for you professionally or personally James would genuinely love to hear from you.You can reach him directly via LinkedIn or through the website below. Everything shared is in complete confidence.ABOUT THE HOST James is an experienced mentor, coach and thought leader who works with a range of clients from FTSE 100 companies, SME´s the NHS and wider public and not for profit sectors.His twenty year career in elite sport initially as a professional rugby player but predominantly as a chief executive has given him an invaluable insight in managing the success, failures and pressures associated with leadership at the highest level.As a high performance coach James specialises in enhancing resilience and leadership development. He is a passionate advocate of the notion that to find lasting fulfilment we need to take a holistic view of high performance. CONNECT & CONTACT The Lonely Leader Academy: The Lonely Leaderwww.thelonelyleader.co.ukThe Lonely Leader's LinkedIn James' LinkedInInstagramhello@thelonelyleader.co.uk THIS SHOW WAS BROUGHT TO YOU BY LONELY LEADER MEDIA NEWSLETTERSign Up to The Leadership Accelerator Newsletter for advice, inspiration and ideas, you'll also receive James' Top 10 Tips for Combating Your Fear of Public Speaking. Hosted on Acast. See acast.com/privacy for more information.

GP Money Matters is a series of special bonus episodes of Talking General Practice sponsored by Wesleyan where we look at key personal finance issues that affect GPs.In this episode GPonline editor Emma Bower speaks to Wendy Baillie, a chartered financial planner and regional manager at Wesleyan Financial Services, about how to decode your NHS pension statement, and why taking a closer look at it is vital for your long-term financial planning. Wendy explains what these statements actually tell you, including crucial details on your pensionable pay, service history, and spousal benefits.She also outlines the most common misunderstandings around NHS pensions, how to navigate issues like the McCloud remedy and the annual allowance threshold, what you should be checking annually to spot errors, and when you may need to seek professional guidance.This episode was produced by Czarina Deen.This podcast is intended for general information purposes only and does not constitute financial advice. Individual circumstances may vary.Useful linksTo learn more about the financial considerations discussed in this podcast, you can book an appointment with a specialist financial adviser at Wesleyan Financial Services. Charges may apply. If you want to find out more about Wesleyan following this podcast, you can visit wesleyan.co.uk/gppodcastAbout WesleyanWesleyan Financial Services supports doctors with advice shaped around the realities of the profession.From complex income structures and portfolio careers to the NHS Pension Scheme and retirement options, its Specialist Financial Advisers work closely with doctors every day. Recognised by the NHS as able to give guidance on the NHS Pension Scheme, Wesleyan brings trusted expertise to key financial decisions. Combining financial planning, investment advice and protection, it helps doctors make confident, informed choices.96% of doctors rated their specialist financial adviser as very good or excellent, reflecting a focused service that helps doctors protect their income, grow wealth and plan ahead with confidence.Remember: The value of investments can go down as well as up, and you may get back less than you invest.Wesleyan Financial Services Ltd (Registered in England and Wales No. 1651212) is authorised and regulated by the Financial Conduct Authority. Registered Office: Colmore Circus, Birmingham B4 6AR. Telephone: 0345 351 2352. Calls may be recorded to help us provide, monitor and improve our services to you. Hosted on Acast. See acast.com/privacy for more information.

Our regular news review is back! In this week's episode Emma, Nick and Kimberley look at advice and guidance and single point of access for referrals after our own survey found that most GPs have seen a referral rejected inappropriately and nearly one in 10 have seen a patient harmed as a result. Meanwhile an interim report by the Health Services Safety Investigations Body (HSSIB) has linked advice and guidance to two patient deaths.They discuss list clearing after an analysis by Nick found that deprived areas have been hit hardest by this process, and figures showed 200,000 patients were cut from GP lists in a single month. Nick explains what this all means for practices and GP funding.And they look at the roll out of tirzepatide or Mounjaro, after an investigation by Kimberley suggested that less than a quarter of eligible patients were prescribed the drug on the NHS over the past year.This week's good news story is about a fall in ICU admissions for infants after roll out of the RSV vaccine.This episode was presented by GPonline editor Emma Bower, deputy editor Nick Bostock and senior reporter Kimberley Hackett. It was produced by Czarina Deen. Useful links●     GPs report patient harm as referral reforms kick in●     AI responses, patronising advice, more work: GP verdict on advice and guidance●     Watchdog links advice and guidance to patient deaths●     Deprived areas hit hardest by 'reckless' list cleaning●     Huge acceleration in list cleaning cuts 200,000 patients in a single month●     Just 1 in 4 eligible patients prescribed tirzepatide, GPonline investigation suggests●     GPs need support to speed up NHS tirzepatide rollout, says MP Hosted on Acast. See acast.com/privacy for more information.

This week we talk about the liver, viral infections, and the NHS.We also discuss blood scandals, needle usage, and Nobel Prizes.Recommended Book: A World Appears by Michael PollanTranscriptThe term “hepatitis” refers to the inflammation of the liver, which can result from all kinds of things, including environmental toxins, the consumption of alcohol, or autoimmune diseases. It can also result from viral infections, and the most prominent liver-inflaming viruses are called viral hepatitis.There are five types of viral hepatitis, A, B, C, D, and E, and each of these viruses are distinct, not part of the same viral family, they're just similarly named because they impact the same organ.Hepatitis A and E are primarily spread through contaminated food and water, and generally resolve on their own, untreated, and cause relatively mild symptoms. Hepatitis B and C are spread through blood and other bodily fluids, and can linger in a host's body for decades before even showing symptoms. Hepatitis D is a parasite of Hepatitis B, and thus only infects people who carry Hepatitis B.Now again, these are all different conditions that just happen to inflame the liver, so impact and treatment also vary quite a lot. As I mentioned, A and E generally present with mild symptoms and tend to go away on their own, while B and C can stick around a long time. There's a vaccine for B, but no cure; you can treat it, but that treatment involves suppressing it, and keeping it suppressed, forever. Hep C, in contrast, is curable, and has been since 2014 using what are called direct-acting antiviral pills, but these pills, which are taken for 8 to 12 weeks, are expensive—ranging from $22-95k without insurance, though that price is often reduced substantially for those with insurance, down to as low as $5. This category of drug coverage is often rejected by insurance companies, though, in part because they're so expensive, that expense the result of little competition in this space; few companies make this type of drug, so those that do can charge more or less whatever they like.Some people with Hepatitis C clear it on their own; about 30% of people who contract it, in fact, clear it within a few months, medication-free. Which is good, because our understanding of this virus is relatively new. Up until 1989, Hep C didn't even have its own name: it was established as its own thing, not Hep A and not Hep B, back in the 1970s, and doctors knew that something that wasn't those two viruses, that was being spread by transfusions, was causing hepatitis symptoms, but they didn't know any real specifics, so they just called it “non-A, non-B hepatitis,” and that name stuck for more than a decade.In 1989 the virus was cloned using molecular techniques (as opposed to simply growing the virus, which wasn't proving fruitful in trying to isolate and identify the thing), and the folks who managed that cloning, and the person who later proved that the genome they cloned, alone, caused the disease, received a Nobel Prize in Medicine for their efforts in 2020.By 1991, antibody tests were available for Hep C, and many countries began screening donated blood for this virus, to ensure it wasn't working its way into their blood supply.And one instance of that screening process, or I suppose, an event that led up to mass screening, and the consequences that followed, are what I'd like to talk about today. The UK's efforts in trying to eliminate Hep C, and England's recently announced near-success in that pursuit.—Hepatitis C is an RNA virus with high genetic variability that makes developing a reliable vaccine difficult. And though somewhere between a quarter and a third of all cases clear on their own, those that don't clear on their own become chronic, lying in wait for twenty to thirty years, slowly accumulating fibrosis—thick scar tissue in the liver—which eventually results in cirrhosis, which means a liver that's so heavily scarred that the organ is no longer fully functional and the damage is permanent. From there, infected people often experience liver failure or hepatocellular (huh-pah-toe) carcinoma, liver cancer.So this virus is a sleeper, and unless it's caught by accident somewhere along the way, it slowly causes damage over time until the damage is too severe to reverse. About 80% of people who have it don't know they have it, and in some parts of the world medical injections are the most common transmitter, but in higher-income areas, it's usually transmitted by injectable drugs.Pre-2014 treatments for Hep C were pretty horrible, involving a combination antiviral therapy called pegylated interferon plus ribavirin that was injected weekly for six months to a year, and this was terribly tolerated by pretty much everyone, causing anemia, depression, and flu-like symptoms for the duration. It also only cured about 50% of people who received the full treatment, and a lot of people had to stop because it caused such ridiculous side effects.Another antiviral called Sofosbuvir (so-FAS-buh-vir), which kept Hep C from replicating in its host, hit the market in late-2013, and that led to a series of direct-acting antivirals that reduced the treatment period dramatically, allowing most people, 95%, to cure their Hep C entirely by taking generally well-tolerated pills for 8 to 12 weeks.These pills were staggeringly expensive from the get-go, with an entire treatment course initially costing about $84,000, or $1,000 a pill. This led to rationing, and saving these pills for the worst-impacted people who already had severe liver damage. There were also pretty stringent requirements attached to their distribution, including that people who received them could no longer drink alcohol, because it was considered a waste to give these crazy expensive, liver-saving drugs to people who would just go and hurt their liver more, anyway.In the UK, the demand for this treatment type was different than in most other countries, in large part because of something that happened back in the 1970s and 80s.The UK's publicly funded healthcare system, the NHS, was in the midst of a shortage of clotting factor, which are plasma proteins and ions that help blood clot and which are used for medical purposes. So they imported a bunch of plasma products from the US, and those products were sourced from the blood of paid donors—and that donor pool included prisoners and people who used injectable drugs. Just one Hep C contaminated blood donation could contaminate an entire batch of blood, and remember, they only started screening the blood supply for Hep C in 1991, and they didn't start treating their blood supply for Hep C until a little before that, 1985, so this was well before they had any idea what was in those blood products they were importing and administering.Consequently, between 1970 and the early 1990s, more than 30,000 NHS patients received transfusions or other blood product treatments contaminated with Hep B, Hep C, or HIV, and about a tenth of those people, around 3,000 patients, have since died of those conditions.The UK government leaned on denial and a refusal to look into the details of this for years, but in 2017 it announced an independent public inquiry into the matter, and in May of 2024, that inquiry concluded that this whole scandal was avoidable, that patients were knowingly exposed to “unacceptable risks,” and that there was a big cover up by government officials, doctors, and other people working with the NHS.As of mid-2026, only a little over 3,200 people of the more than 18,500 who registered claims, demanding compensation from the government because they were impacted by this scandal, have been paid out. The expected total expense for the UK government is on the order of 12.8 billion pounds, but a lot of people who are probably due a payout, and who are in poor and deteriorating health as a consequence of all this, don't yet have a sense of when they'll receive their payment.Back in 2016, before all that came to a head, the UK set itself an aggressive goal: to eliminate Hep C by the WHO's 2030 target, or before. It then ran a competitive tender for antivirals, inviting medical suppliers to submit competing bids, resulting in the largest single medicine procurement program in the NHS' history. The pharmaceutical companies that won their bids were also obliged, as part of the agreement, to help fund efforts to identify undiagnosed but infected patients, in addition to supplying antiviral pills, and this combination of investment and application led to the deployment of new tests and scanning machines, free postal test kits, the hiring of specialists, and services that focused on prisons and drug users.The impact of all this has been significant: a more than 61% decline in infections from 2015 to 2024, nearly half of all drug users with Hep C had cleared the virus in that time, and deaths from Hep C are down 36% over the past decade.The WHO treatment-coverage target—the percentage of people who are diagnosed getting treatment—was 80%, and England has hit 81.5%, which was recently announced to much fanfare. It hasn't yet hit the diagnosis target, however, which is to diagnose 90% of people who are estimated to have Hep C; they've hit 84.6%, which is still quite a lot of progress, even if they're not yet where they'd like to be. That's all based on models, of course, as are the assumed number of infections among people who use injectable drugs, which is also a spot where England is currently flagging; there's no centralized system in England to monitor needle and syringe provisions, and reinfection rates are around 8.8 per 100 person-years among people who had injected within three years of receiving treatment, and that rate is even higher for people who have ever been to prison, around 9.4 per 100.What that means in practice is that the English government overall has done a pretty astounding and effective job at negotiating their relationships with pharma companies and getting detection on track at that scale, but on more ground-level issues that are, interestingly, a lot cheaper to implement, but at times more politically complicated because of public sentiment about drug use and drug users, they're doing a lot less well—and important to note here is that these outcomes vary a bit across the four programs being run across the UK. Scotland and Wales are doing relatively better and worse in some regards compared to England, for instance.Also worth noting here that while England is broadly doing a great job with Hep C diagnosis and treatment, they aren't the first to achieve those WHO-set goals: Egypt reached Gold tier status according to the WHO's Hep C guidelines in October of 2023, at that point having diagnosed 87% of people who have the virus, and treating 93% of those who were diagnosed. They managed to cut incidence of the virus by 97% in just 8 years, leaning on a system of high-yield testing—they tested more than 60 million people during those 8 years—alongside a production scheme that included local manufacturing of antivirals, making them more available and affordable.All of which are generally good signs about where Hep C testing and treatment is going, at least in these regions. And it paints a optimistic picture for other countries that might want to replicate some of what's working within their own borders.Show Noteshttps://www.bbc.com/news/articles/c75gk620r22ohttps://en.wikipedia.org/wiki/Infected_blood_scandal_in_the_United_Kingdomhttps://en.wikipedia.org/wiki/Hepatitis_Chttps://en.wikipedia.org/wiki/Viral_hepatitishttps://en.wikipedia.org/wiki/Hepatitis_Bhttps://www.healthline.com/health/hepatitis-c/treatment-costshttps://www.who.int/news-room/fact-sheets/detail/hepatitis-chttps://publichealthscotland.scot/publications/surveillance-of-hepatitis-c-in-scotland/surveillance-of-hepatitis-c-in-scotland-progress-on-elimination-of-hepatitis-c-as-a-major-public-health-concern-2025-update/https://www.emro.who.int/media/news/egypt-becomes-the-first-country-to-achieve-who-validation-on-the-path-to-elimination-of-hepatitis-c.htmlhttps://www.gov.uk/government/publications/hepatitis-c-in-england-and-the-uk/hepatitis-c-in-england-2025https://www.england.nhs.uk/2026/08/100000-people-receive-treatment-to-cure-deadly-hep-c-virus-on-nhs-in-just-ten-years/https://www.hepctrust.org.uk/blog/2019/04/hepatitis-c-trust-welcomes-elimination-deal-hepatitis-c-and-calls-government-backed/https://commonslibrary.parliament.uk/research-briefings/cbp-10099/https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/reports/global-hepatitis-report-2026 This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe

The revelation that a paedophile had changed his name more than 20 times to hide his past has renewed pressure on the government to change the law. Jason Brown was first convicted 12 years ago. He has now pleaded guilty to a further offence. There's been campaigning for many years for it to be illegal for sex offenders to change their name, as many use their new identities to avoid being monitored. The Labour MP for Rotherham Sarah Champion is one of those calling for this legal change and she tells Nuala why.Millions of Filipinos work overseas to help raise money for their families back home. And of these millions more than half are women. Here in the UK tens of thousands of Filipinos work in the NHS, they are one of the most common non-UK nationalities for nurses and health visitors in our health system. But what is life like for those who are left behind? Poet and nurse Romalyn Ante's debut novel, the Left Behind Child, explores the teenage years of Neneng, who is eleven when her mother, Rosa, leaves to work as a nurse abroad. Romalyn tells Nuala McGovern how her true story of being a ‘left behind child' influenced her writing. The parents of 30 children have told the BBC they fear they were given the wrong sperm or egg donors, during IVF treatments, in northern Cyprus. Fertility clinics in the Turkish-occupied territory are loosely regulated and are popular with British people who need medical help to have a baby. A small team of journalists first exposed this IVF scandal earlier this year - which led to many more people coming forwards. The BBC has now found the majority of cases are linked to one clinic and a small group of staff. Nuala hears from one of those families, a woman called Rachel, who was given the wrong sperm donor. She is joined by Investigative Journalist Anna Collinson and fertility lawyer, Natalie Gamble. From Dua Lipa to Zendaya, the bandana is the 90's accessory that's making a come back. In the heatwaves it has proved practical as well as stylish. But the simple square or triangle of fabric with the paisley design has a history with a range of meanings and cultural references, from workwear and protest movements to fashion and self-expression. Amber Butchart, Fashion & textile historian, and the author and broadcaster Emma Dabiri discuss the history behind the comeback. Presenter: Nuala McGovern Producer: Helen Fitzhenry

This week on the Full of Beans podcast, Han is joined by Dr Stella Kozmér, an NIHR SPCR-funded Postdoctoral Researcher at the University of Exeter, a Researcher at the University of Oxford, and an incoming Trainee Clinical Psychologist at the University of Oxford. Coming from an Eastern European background, Stella's research focuses on the identification and management of binge eating disorder and bulimia nervosa in primary care settings, using mixed-methods research to inform NHS clinical guidelines, policy and practice. Her work is driven by her own lived experience, which she integrates into the core of what she does.In This Episode:Stella's personal and professional journey into binge eating disorder researchHow Stella felt in recognising BED after a decade of not having a name for itWhy Stella felt stigma and shame disclosing her mental health issues in healthcareWhy lived experience is a strength in research, not a bias to hideWhy primary care screening tools for binge eating disorder and bulimia fall shortThe problem with SCOFF and other outdated eating disorder screening criteriaHow weight stigma affects whether binge eating disorder gets identified at allWhy GPs are hesitant to talk about BED without services to refer patients toThe real-world cost of untreated binge eating disorder and its comorbiditiesHow to use the diabetes care model as a blueprint without more fundingA review of GLP-1 medications for binge eating disorderWhat the GLP-1 evidence does and doesn't tell us, and the misuse risks to considerWhy treatment for binge eating disorder must be personalised, not one-size-fits-all⚠️ Content note: this episode discusses eating disorders (including binge eating disorder and bulimia), disordered eating, weight stigma, obesity, and prescription medication. Please take care while listening.Connect with us:Subscribe to the Full of Beans PodcastFollow Full of Beans on InstagramCheck out our websiteListen on YouTubeConnect with Dr Stella Kozmér: via LinkedInRead Stella's research via Research Gate

Each week, RNIB Connect Radio's Allan Russell sits down with Simon Antrobus, CEO of RNIB, to look at some of the big stories coming from the UK sight loss charity.This week Simon talks about two positive NHS stories, importance of eye checks, and free sighted guides for the Edinburgh Festival.If you, or someone you know, would like information on the support and services available from RNIB, go to www.rnib.org.ukYou can call our Helpline on 0303 123 9999 or ask your Smart speaker to call RNIB's Helpline.#RNIBConnectImage shows Headshot photograph of Simon Antrobus smiling for the camera. He is a white man with neat, short brown hair, dressed in a white shirt and charcoal suit jacket.

Counting is underway – but will Nigel Farage win, or Count Binface? We speak to the satirical alter ego of comedian Jon Harvey.Also in the programme: Nurses complain of "inhumane" conditions in hospitals as the heatwave results in NHS staff dripping in sweat from "head to toe". And luxury department store Harvey Nichols has been bought by the owner of Sports Direct, Mike Ashley – but can he resurrect the ailing business?

In the final episode of this series, Professor Habib Naqvi MBE looks ahead to the future of equitable healthcare. From the economic impact of health inequalities and rebuilding trust with underserved communities to the role of patients in shaping healthcare policy, he explores the changes needed to create a fairer NHS. The episode also examines emerging challenges in health equity, lessons from international approaches, and the reasons for optimism about the future of race equity and healthcare. Timestamps: ·       1:07 – Equity: A Moral and Economic Priority ·       04:06 – The Bigger Picture ·       05:28 – Building Trust ·       07:50 – International Partnerships ·       10:00 – New Trends ·       11:48 – Patients and Communities ·       14:30 – Intersectionality ·       15:59 – Looking Forward ·       17:46 - Optimism

What roles do leadership, workforce equality, and accountability play in achieving health equity? In Part 2, Professor Habib Naqvi MBE explores the link between staff experience and patient outcomes, discusses the realities faced by ethnic minority NHS staff, examines why translating good intentions into meaningful action remains challenging, and explains how data, leadership, and openly addressing racism are essential to driving lasting change across the healthcare system. Timestamps ·       01:01– Workforce Inequality ·       05:37 – From Policy to Action ·       07:29 – Data Limitations ·       09:53 – The 'Model Organisation' ·       12:34 – Accountability

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that underscore the dynamic shifts and groundbreaking progress within the industry. Recently, Akeso's ivonescimab received a landmark approval for first-line treatment of non-small cell lung cancer (NSCLC) in China. This marks a significant shift in China's regulatory environment, which is increasingly fostering innovative treatment options. Ivonescimab's approval not only enhances Akeso's standing in oncology but also provides new hope for NSCLC patients, a cancer type notoriously difficult to treat. In the arena of mergers and acquisitions, Alfasigma has strategically expanded its reach by acquiring key assets from Nordic Pharma. This acquisition opens doors to new therapeutic areas like arthritis, women's health, and critical care—an astute move to diversify offerings and enhance global market presence. Such strategic expansions are essential for companies aiming to maintain competitive edge and explore untapped markets. Eli Lilly has taken legal action against six U.S. companies involved in unauthorized sales of its experimental weight-loss drug, retatrutide. This highlights ongoing challenges in intellectual property protection, emphasizing the balance between innovation safeguarding and market expansion. The legal actions are part of broader efforts to preserve public safety and ensure proper distribution channels for groundbreaking therapies. On the quality control front, Fresenius faced a setback with the recall of a batch of Actemra biosimilars due to glass particle contamination concerns. This incident serves as a stark reminder of the critical role rigorous quality assurance plays in pharmaceutical manufacturing, especially as biosimilars gain traction for their cost-effectiveness and accessibility. In an intriguing blend of technology and healthcare, Samsung Electronics has secured FDA clearance for its Galaxy Buds earphones to function as over-the-counter hearing aids. This development illustrates the increasing convergence of consumer electronics with medical devices, offering innovative solutions to enhance accessibility in hearing health. Turning to psychedelic therapies, Definium Therapeutics reported significant success in its Phase 3 trials for an LSD-based formulation targeting generalized anxiety disorder. Building on earlier successes in depression studies, Definium is paving the way for psychedelic compounds in mainstream medicine. The results not only bolster confidence in such therapies but also signal a potential paradigm shift in treating mental health disorders. Moreover, Oracle Health has introduced an upgraded patient portal featuring an AI assistant designed to simplify medical records management and appointment scheduling. This advancement is part of a larger trend towards integrating artificial intelligence into healthcare systems to improve patient engagement and streamline processes, ultimately enhancing healthcare delivery efficiency. BridgeBio's ATTR stabilizer Attruby achieved impressive quarterly sales of $222 million, nearing blockbuster status as it captures significant market share in treating transthyretin amyloidosis (ATTR). This success underscores the growing importance of small molecule therapies in addressing complex cardiovascular conditions and reflects an industry trend towards stabilizer-first markets. InduPro has successfully raised $77 million in Series B funding supported by industry leaders like Sanofi and Lilly. The investment is set to propel their cancer pipeline forward with a focus on induced proximity and bispecific antibody platforms—innovations poised to revolutionize oncology treatment by enhancing drug specificity and efficacy. On the regulatory front, Chiesi UK's delayed-release mercaptamine received NHS endorsement for cystinosis treatment—an advancement that expands therapeutic options for patients requiring cystine-depleting therapy. Such regulatory support is crucial for facilitating access to innovative treatments for rare diseases. Amidst these developments, Gilead Sciences licensed MacroGenics' bispecific antibody program—a strategic move to bolster its oncology portfolio through milestone payments and royalties. This reflects a broader industry pattern where larger pharmaceutical companies seek pipeline diversification through strategic partnerships and acquisitions of innovative technologies. In vaccine development news, StablePharma's SPVX02 tetanus-diphtheria vaccine achieved promising Phase 1 results without refrigeration requirements—an innovation that could significantly enhance global vaccination efforts by overcoming cold chain distribution challenges. Finally, Insilico Medicine stands at the forefront of AI integration into drug discovery processes under CEO Alex Zhavoronkov's leadership. By promoting a 'fail-fast' approach at the Bio International Convention, Insilico aims to accelerate drug development timelines while reducing costs—a strategy indicative of biopharma's evolution towards more data-driven decision-making processes. These stories collectively highlight an era marked by rapid innovation within pharmaceuticals and biotech sectors. As companies navigate these complexities through scientific advancements and strategic maneuvers alike—there lies immense potential not only for enhancing patient care but also driving economic growth across global healthcare landscapes.Support the show

Following our eye-opening episode on Australian optometrists unionizing in response to growing corporate pressure, The 20/20 Podcast turns to the United Kingdom—and the warning signs are just as important. Dr. Harbir Sian sits down with Dr. Keyur Patel, an experienced UK optometrist who has worked across corporate, hospital and independent practice settings and also trained in the United States. Together, they examine how decades of undervaluing clinical services, increasing corporatization and a growing dependence on retail revenue have reshaped optometry in the UK. Keyur also shares his own experience of being dismissed from a refractive surgery company despite no concerns about his clinical ability—because he was not converting enough patients to laser surgery.The conversation then moves to one of the most consequential issues facing the profession: workforce oversupply. With more optometry schools opening and more graduates entering already saturated markets, compensation can be driven lower while individual optometrists lose negotiating power. Keyur and Harbir discuss reports of locum positions paying as little as £25 per hour and the uncomfortable economics behind it: when there are more optometrists competing for fewer desirable jobs, employers gain leverage, salaries decline, and clinicians may feel increasingly pressured to accept working conditions or business models they otherwise would not. Combined with low reimbursement for eye examinations and diagnostic services, that environment can push practices further toward KPIs, spectacle sales and other commercial metrics simply to remain profitable.For optometrists in Canada and the United States, the UK and Australia may offer a glimpse of what can happen when these changes are allowed to compound over decades. More schools, more graduates, lower professional compensation, weaker negotiating power, increasing corporate influence and the gradual erosion of clinical autonomy do not happen overnight—but they can fundamentally change a profession. At the same time, Keyur offers a powerful counterexample: his independent practice walked away from the low-fee NHS sight-test model and built a practice where patients willingly pay more because they value the quality of care, relationships and experience they receive. The message is clear: if optometrists do not actively protect the value of their clinical services and the independence of the profession, others will define that value for them.Love the show? Subscribe, rate, review & share! http://www.aboutmyeyes.com/podcast/

⚠️ This episode discusses antidepressants, mental health treatment, withdrawal and sensitive topics around psychiatric medication. Please seek professional guidance before making any changes to your medication.This week I'm joined by Dr Mark Horowitz, clinical research fellow in psychiatry, co-author of the Maudsley Prescribing Guidelines, and one of the most important voices in the world right now on antidepressants and how to come off them safely.We explore the science behind antidepressants, what they actually do to the brain, and what nobody told you about coming off them.Dr Mark Horowitz is a clinical research fellow at University College London and North East London NHS Foundation Trust. He co-authored the Maudsley Deprescribing Guidelines, which have begun to change clinical guidance on antidepressant withdrawal worldwide. His research on tapering and withdrawal has been published in leading medical journals and has directly influenced NHS and international prescribing guidelines. He founded the National Prescribing Support Service and has trained clinicians at Outro Health in America in safer tapering approaches. He has personal experience of antidepressant withdrawal, which led him to dedicate his career to helping others through the same process.What we explore together:Why 1 in 6 people in England are on antidepressants — and whether we are overprescribingWhat antidepressants actually do to the brain and why the chemical imbalance theory is misleadingWhy the clinical trial data on antidepressants is far less impressive than most people realiseThe emotional blunting effect — what it is, why it happens and what to do about itWhy 85% of people recover from depression within 12 months with no intervention at allWhat withdrawal actually feels like — and why doctors so often get it wrongHow to taper safely and why doing it too fast causes so much unnecessary sufferingWhat the alternatives to antidepressants are and why they are rarely offered firstLove, Sarah Ann

In this explainer episode, we've asked Dr Antonio D'Alessio, Medical Oncologist at Guys and St Thomas Foundation Trust, to explain cancer vaccines and how they work. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What are cancer vaccines and how do they work? My name is Florence Cornish, and today I'm joined by Antonio D'Alessio, who is a medical oncologist ay Guy's and St Thomas' Foundation Trust and King's College. And he's going to be telling us much more about the topic. So Antonio, before we get into cancer vaccines, I wanted to first ask you about cancer. I know it's a pretty broad term, and it refers to the uncontrolled growth of cells in the body, but maybe it would be helpful for you to explain a little bit more about what cancer actually is, like what that term means, especially for listeners out there who might not have that scientific background. Antonio: Yeah, of course. And first of all, thanks for inviting me today. Well, that's a big question. The point is that we know that in our bodies there are billions of cells, and all of these cells, they divide, they do their job, and they know when to die on schedule. The point is that sometimes there are cells that ignore this instruction and just keep reproducing and growing, and this is when cancer grows. Our bodies have systems, which is the immune system, to recognize when this happens so that the immune system can recognize the cancer cells that are growing too much. They attack them and destroy them. But unfortunately, sometimes cancer is quite clever, they manage to escape from the immune system and starts growing without control, and that's when cancer starts. Florence: And so, what are the standard treatments that we use for cancer at the moment? Antonio: Well, broadly speaking, I would say that we have three types of cancer treatments. One, it's surgery, where we just cut the cancer out. Then we have radiotherapy, where we basically induce targeted damage to the cancer. And then we have a very broad umbrella term that is systemic therapy. Systemic therapies can be chemotherapy, can be targeted therapies, and that can be immunotherapy. In particular, immunotherapy is quite exciting because over the past 20 years, we have learned how to boost the immune system of patients, so that's the white blood cells, the immune system of patients that can recognize cancer cells and attack them. Sort of imagine that cancers hide behind an invisibility cloak, and immunotherapy helps unveil the cancer so that the immune system can recognize the cancer again and attack it. And vaccines and cancer vaccines are part of this family of immunotherapy drugs. Florence: Yeah so speaking about that, I think lots of listeners might have heard of the term cancer vaccine before, obviously, its the topic of this episode. And I think the term cancer vaccine sounds very interesting and promising, but also maybe a little bit intimidating as well. So maybe you could tell me more about what a cancer vaccine is kind of at the most basic level. Antonio: Well, cancer vaccine is a vaccine, and we have received so many vaccines in our lives that our body basically has learnt already how to process a vaccine. Imagine a vaccine as a wanted poster. So, we give the body the instructions to recognise something that shouldn't be there, and the immune system knows how to do it. So, the job of the immune system is to recognize strangers in our bodies - that can be microbes, bacteria, viruses, and also cancers. And sometimes with a vaccine, we sort of help the immune system to do its job a bit better. And with vaccines, we provide the instructions to recognize these strangers in our body and help the immune system to, to get rid of them. And in particular, for cancer vaccines, we have different types of cancer vaccines. There's a family of cancer vaccines that are called preventative, where we can try to give a vaccine even before the cancer develops to reduce the risk that the cancer develops. And, this is more early in the development. While we have, another family of cancer vaccine, which are mostly mRNA cancer vaccines that are called therapeutic. So these are cancer vaccines that are given to patients who already have cancer, maybe who had the surgery for their cancers, so that the aim of the cancer vaccine is to boost immune system and reduce the chances that the cancer comes back after surgery, or, help other types of immunotherapy work better together with vaccine against the cancer. Florence: So, I think for me at Genomics England, the mRNA cancer vaccines are probably most relevant to the work that we do here as an organization. Could you explain a little bit more about how those ones work specifically? Antonio: Yeah, that's an exciting field, right? The mRNA vaccine. So, let's split this into different words, mRNA and vaccine. We have just covered what vaccine means. We just have to think mRNA as just instructions. So we give the body of the patients the instruction to recognize the cancer. And the mRNA is basically the instruction for the immune system to recognize some of the proteins that are expressed on the cancer cells, so that's the white blood cells, the own white blood cells of the patients that can be more alert and identify the cancer cells if they are around. And in particular, imagine when we give the mRNA vaccine, it's like we are giving the picture of a suspect to the police, right? The police is the immune system of the patients, and the suspect is the cancer. And so, the immune system, so the police of our body, can go around the body, can go around the bloodstream, can go around the organs, and if they see the suspect, they are, they are already alerted, and they can tackle it, attack it, and destroy it before it develops into, into a cancer that can be seen on the scans.   Florence: And are these types or other types of cancer vaccines being used in the clinic at all in real medical settings already? Antonio: Well, I wouldn't say that we are using that in clinical practice, but probably in the future we will, and we are working hard to make sure that we will be able to use cancer vaccine for our patients. At this stage, we are using cancer vaccines as part of clinical trials, and these clinical trials cover different types of cancer types, different types of setting, together with other drugs or given alone after surgery, for instance. And the NHS England, Genomics England and NIHR, they launched this massive infrastructure that is called the Cancer Vaccine Launchpad. And it is aimed specifically to match the NHS cancer patients with personalized mRNA vaccine trials, so that once we have the results of those trials and we are ready to deploy it in clinical practice, then we already have the infrastructure to do that promptly, hopefully in the next future. Florence: Mm-hmm. Yeah, so do you see a future where cancer vaccines are used in routine care? Antonio: Well, we are working towards that. And I, and I do see a future where we're going to use that. I don't know when. Probably it will take still a few years. But the, for example, in the UK and in England in particular, we have a national cancer plan, and the national cancer plan for this year has identified cancer vaccine as a top priority for our health system. And this is because this is a technology that can be scalable, that can be widely deployed once it's demonstrated to be working. And at this stage, there are still some open questions, like which cancer types in which setting, which patients would benefit from it. But once we address these open questions in clinical trials, then I do believe that we'll be able to use that in the, in the future. Florence: I think we'll finish there. Thank you so much, Antonio, for coming on and for taking the time to talk to us. Antonio: Thank you Florence, and thank you for the invite. Florence: If listeners want to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk or wherever you get your podcasts. Thank you for listening.

Send us Fan MailSimon and Lee open with birthday banter that spirals into scientists launching an OnlyFans-style subscription service to replace cut research funding, then a viral clip of bonobos defusing a fight with cuddles instead of violence. The real conversation catches fire when Simon reads out an AI-generated reply from a prospective PhD student, and the two dig into what gives it away (that telltale word "specifically"), whether he owes the applicant honest feedback, and how wanting AI to skip the reading is really no different from wanting it to do your weights for you at the gym. Simon closes things out nursing a sprained wrist from coming off his bike on Thursday, with a shout-out to the NHS staff who patched him up.MentionedOnlyFans – subscription platform typically associated with adult content; raised as a tongue-in-cheek pitch after hearing scientists had lost fundingMarmosets – small primates; the animal whose research funding was cut, prompting the joke about launching an OnlyFans-style site insteadInstagram – social media platform; where a viral bonobo video turned up in the feedBonobo monkeys – primate species known for resolving conflict through physical affection rather than aggression; a clip of an older bonobo defusing a fight between two younger males prompts a wider discussion of animal behaviour versus internet contentTikTok – video platform; cited for algorithmic content moderation, including euphemisms that have replaced certain censored wordsAlice  – addressed directly mid-conversation ("I wonder if Alice is thinking, go back to the bonobos")Daily Mail – UK tabloid; invoked as the kind of outlet that wouldn't report favourably on NHS staffNHS – National Health Service; A&E staff praised for handling a high volume of patients with care and professionalismGet in touch with Lee and Simon at info@midlifing.net. ---The Midlifing logo is adapted from an original image by H.L.I.T: https://www.flickr.com/photos/29311691@N05/8571921679 (CC BY 2.0)

Riley speaks to Foxglove's Donald Campbell about the campaign to prevent Palantir from working with the NHS, but before we get to that, we have to talk about… fictive elven graves. And real Bronze Age burial sites. And a man in Texas who's willing to move heaven and earth in order to view anime. Get more TF episodes each week by subscribing to our Patreon here! Learn more about Foxglove and support them here! RILEY ALERT Check out No Gods, No Mayors here! HUSSEIN ALERT Check out 10k Posts here! MILO ALERT Check out Milo's tour dates here: https://www.miloedwards.co.uk/liveshows NATE ALERT Nate's band Second Homes has just released their debut album and you can stream it for free here! Trashfuture are: Riley (@raaleh), Milo (@Milo_Edwards), Hussein (@HKesvani), Nate (@inthesedeserts), and November (@postoctobrist)

Episode 82 - Matthew Whitty, former NHS England Director of Innovation, Research and Life Sciences and now Director of Commercial Partnerships at MDClone, discusses NHS data strategy, safe AI adoption and protecting patient privacy.Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

Ask Rachel anythingA listener parenting a teen son wrote to say both of them felt pretty stunned when he was rejected from the university he'd set his heart on. She asked for the best way to help our teenagers cope with this sort of disappointment. I thought it was a great question and a good opportunity to also look at how we parents can best navigate when our teen has worked for years toward a dream - a top university place, exam results, a team, a part - and it doesn't happen. The disappointment can feel earth‑shattering for them and gut‑wrenching for you.In this episode I talk with Dr Dominique Thompson, award‑winning GP and young people's mental health expert, about how to support teenagers through big disappointments such as university rejection, exam failure, and missed opportunities – without rescuing them or minimising their feelings.We explore:What teens are actually grieving when things go wrong – including the loss of an imagined futureHow to validate their emotions while gently stopping catastrophic thinkingThe difference between building resilience and teaching kids to suppress their feelingsWhy today's culture of perfectionism and “being the best” is driving anxiety, burnout and fear of failureHow to help teens separate self‑worth from grades, offers and achievementsPractical ways to prepare teens for university life, academic stress and independenceWhen dropping out isn't the only option – how to press pause, get help and return strongerWhat to do if your teen feels “left behind” while friends move on to university or big opportunitiesHow parents can be a “safe harbour”: supportive, boundaried, and not adding their own disappointment to their teen's loadIf you're a parent wondering how to respond when your child says, “I've failed you,” or “There's no point trying,” this conversation will give you concrete language, mindset shifts and step‑by‑step strategies to help them cope, reframe, and find a new path forward.Dr Dominique Thompson: is a multi-award winning former GP, young people's mental health expert, TEDx speaker, author and educator, with over two decades of NHS clinical experience.She is author of The Student Wellbeing Series for young people, and co-author of How to Grow a Grown Up (PenguinRandomHouse) for parents.dominique.thompson@me.comwww.buzzconsulting.co.uk https://www.instagram.com/drdomthompson/https://www.facebook.com/drdomthompson/https://www.linkedin.com/in/dominique-thompson/Support the showPlease hit the follow button if you like the podcast, and share it with anyone who might benefit. You can review us on Apple podcasts by going to the show page, scrolling down to the bottom where you can click on a star then you can leave your message. Please don't hesitate to seek the advice of a specialist if you're not coping. There's no shame in reaching out for support. When you look after yourself your entire family benefits.Find all the tips from the episdoe on Substack: My emailMy website has a blog, searchable episodes, and ways to contact meInstagramFacebookYou can reach Susie at www.amindful-life.co.uk

Send us Fan MailJak Inhibitors update for alopecia areata Tommy Hall is originally from Maine, near Boston, but now lives in London.He first came on the podcast in February 2023, after experiencing alopecia areata, which evolved into universalis, and lost all of the hair on his entire body. He began using JAK inhibitors to treat his condition, which were not approved on the NHS at the time to treat hair loss.He joins me today with an update on his progress, sharing that he has now tried three different types of JAK inhibitor, the challenges that have come with this, and even the clinical trial he is now participating in.Tommy says that he has come to terms with his hair loss, and how this experience has forced him to challenge what he felt about himself, his identity and his relationship with how he looks. He has seen great success in the last 18 months, with his SALT score going from 100 to 7!Connect with Tommy:InstagramAlopecia Connection Podcast Hair & Scalp Salon Specialist course Support the showConnect with Hair therapy:FacebookInstagramTwitterClubhouse- @Hair.TherapyHair Therapy WebsiteDonate towards the podcast Start your own podcastHair & Scalp Salon Specialist Course ~ Book now to become an expert! 

This morning, in the first thirty minutes after you woke up, who did the morning belong to? Did it belong to you? Or did it belong to your inbox, your notifications, the news, and the chaos of getting everyone else out of the door? For many senior leaders, the answer is the latter. The morning that had the potential to set them up for everything that followed was handed over before they had even fully woken up. Nobody took it from them, they gave it away.In this episode of The Lonely Leader Podcast, James Rule returns to one of the most consistently requested topics in the back catalogue and goes significantly deeper than the original Episode 4. This episode is about standards, because how you start the morning is a direct reflection of the standards you hold yourself to and the morning audit James shares at the end will make that uncomfortably clear.James builds a practical framework for reclaiming the first hour of your day, a set of non-negotiables that take fifteen minutes and change how the rest of the day feels.KEY TAKEAWAYSWhy most leaders have a morning reaction rather than a morning routine and the difference it makes.The Three and Three practice revisited, expanded, and built upon from Episode 4.Why the phone has to wait and how to handle every objection to that.Why a good morning starts the night before.The complete framework for building a morning that serves you, adapted to your own life and rhythm.A five-day morning audit challenge that reveals exactly what you have been accepting.Accelerate your growth and development with The Lonely Leader Academy If you want to work through some of these areas in more depth, to accelerate your learning and access tools, tactics and tips to drive performance and enhance fulfilment then check out The Lonely Leader Academy: https://tll.academyRELATED EPISODES FROM THE ARCHIVEEpisode 4 - High performers do this everyday to empower their mindsetEpisode 33 - High Performance Pledges Episode 93 - Inside The Lonely Leader: My story, my philosophy, my purposeABOUT THE HOST James is an experienced mentor, coach and thought leader who works with a range of clients from FTSE 100 companies, SME´s the NHS and wider public and not for profit sectors.His twenty year career in elite sport initially as a professional rugby player but predominantly as a chief executive has given him an invaluable insight in managing the success, failures and pressures associated with leadership at the highest level.As a high performance coach James specialises in enhancing resilience and leadership development. He is a passionate advocate of the notion that to find lasting fulfilment we need to take a holistic view of high performance. CONNECT & CONTACT The Lonely Leader Academy: The Lonely Leaderwww.thelonelyleader.co.ukThe Lonely Leader's LinkedIn James' LinkedInInstagramhello@thelonelyleader.co.uk THIS SHOW WAS BROUGHT TO YOU BY LONELY LEADER MEDIA NEWSLETTERSign Up to The Leadership Accelerator Newsletter for advice, inspiration and ideas, you'll also receive James' Top 10 Tips for Combating Your Fear of Public Speaking. Hosted on Acast. See acast.com/privacy for more information.

 In this rapid-fire episode, Habib Naqvi answers key questions on health equity, race and the future of the NHS. From the most overlooked determinants of health and common misconceptions about health inequalities to leadership, the achievements of the NHS Race and Health Observatory, and the changes needed to create a fairer healthcare system, this episode offers concise insights for anyone interested in improving health outcomes and advancing equity.

In this episode of Chewing It Over, Jack speaks with Luke Kellaway about his MSKMag article, The Biggest Wins in the NHS Are Cheap, exploring whether healthcare innovation has become too focused on expensive technology at the expense of simpler solutions that already work.Luke highlights the enormous burden musculoskeletal conditions place on the NHS and argues that relatively inexpensive initiatives can produce substantial improvements in waiting lists, patient outcomes and service efficiency. Yet these less glamorous interventions can struggle to attract the attention given to AI and digital health pilots.The conversation questions what healthcare actually means by efficiency. Saving clinicians time with technology sounds valuable, but if that additional capacity simply allows more patients to enter an already constrained pathway, it may increase spending rather than reduce it. Improving one part of a system also achieves little if patients simply reach the next bottleneck faster.Jack and Luke discuss the importance of examining and redesigning clinical workflows before adding technology. Rather than assuming AI will fix inefficient systems, organisations should first understand where delays occur, streamline existing processes and then identify where technology genuinely adds value.They also explore the challenges surrounding healthcare AI, procurement and medical-device regulation. As increasingly sophisticated technology enters clinical practice, both managers and clinicians need enough digital literacy to question how these systems work, whether they are appropriately regulated and what they mean for patient safety.Ultimately, the discussion makes the case for pragmatic innovation: empower clinicians, improve pathways, scale interventions that already work and introduce technology where it solves a clearly defined problem—not simply because it is new.

Welcome back for Part 2 of our Clara Bow series where we unpack how this young girl from Brooklyn became the muse of Taylor Swift, Stevie Nicks and Margot Robbie!Looking at her relationship with the press, struggles with mental health, financial situation and final years, we're going to unpack Clara's impact on both culture and history. Because as it turns out, Hollywood and indeed society haven't really changed how we speak about or view women since Clara Bow!Shout out to our incredible researcher Grace McCamish for pulling this together, and if you're wanting more Hot History you can follow along on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠Substack⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and of course, right here! 'Til next week, Ainslie xPlease take care while listening with the sensitive themes mentioned at the top and should you require assistance please use the below:In Australia, support is available 24/7 by calling or texting 0477 131 114 (lifeline) or 1300 22 4636 (Beyond Blue).In the USA,  support is available 24/7 by calling or texting 988 (⁠⁠988 Suicide & Crisis Lifeline⁠⁠) or texting HOME to 741741 for the ⁠⁠Crisis Text Line⁠⁠.In the UK, support is available 24/7 by calling NHS 111  (NHS) or  ⁠⁠116 123⁠⁠  (Samaritans)

TRIGGER WARNING: this episode discusses eating disorders, disordered eating, body image, weight loss, body comparison, celebrity bodies and potentially triggering content around food and appearance. Please take care of yourself while listening.if you'd prefer to skip our highs and lows, our main conversation starts at 19:30.in this episode we address the recent conversation surrounding Ariana Grande and, more broadly public body criticism, celebrity culture and the way we talk about people's appearances online.we get into why we feel so uncomfortable commenting on someone else's body, even when those comments come from a place of genuine concern. we talk about the difference between expressing concern and contributing to harmful body discourse, whether celebrities have any responsibility for the images they put into the world, and whether the public has any right to expect an explanation about someone's health.we also talk about our own experiences with body image and why seeing certain content online can affect us differently depending on where we are in our own journeys. we also chat about the potential impact of seeing this kind of content when you're younger, whether trigger warnings actually help, and what we can do when we notice the internet starting to negatively affect our own relationship with our bodies.It's a messy, nuanced conversation, and we're very aware that there isn't one “right” way to talk about something this complicated. we're sharing our own thoughts and experiences rather than pretending to have the answers, and, as always, we'd love to hear yours.USEFUL RESOURCES

RHLSTP Book Club #191 - Middle Aged Women Get Sh*t Done - Richard is at the Podcast Room chatting to friend and comedian Lucy Porter about her fun and fascinating book, Middle Aged Women Get Shit Done. Is it just for women or should men read it too? Should it be pulped because of what it says about Scrabble? What does it mean to be a Linda? Would the NHS collapse without middle-aged women? What about the middle-aged men? Plus some chat about quizzing and whether Rich is the best at Mastermind.Buy the book here https://uk.bookshop.org/p/books/middle-aged-women-get-sh-t-done-a-manifesto-or-a-cry-for-help-lucy-porter/e627fe5b294dcdeb?ean=9781035441570See Lucy at the Fringe https://www.edfringe.com/tickets/whats-on/lucy-porter-the-name-of-the-games-wipSUPPORT THE SHOW!See details of the RHLSTP LIVE DATES Watch our TWITCH CHANNELBecome a badger and see extra content at our WEBSITE Buy DVDs and books from GO FASTER STRIPEAudio mix by Ben Evans (NTO)Thanks to Chris Evans (NTO)Recorded at the Podcast Room Hosted on Acast. See acast.com/privacy for more information.

Beloved TV doctor, children's author and NHS paediatrician Dr Ranj Singh tells James O'Brien the extraordinary story behind the smile - from the collapse of the life he thought he was supposed to want, to the painful process of working out who he really was.He speaks candidly about growing up in a traditional Indian family, the pressure to follow a respectable path, and the emotional cost of spending years trying to fit expectations. He recalls his sexuality being “outed” to his parents before he was ready, the heartbreak and confusion that followed, and the therapy that helped him understand his identity and start living more truthfully.They also explore his career in medicine, his decision to step back after decades in the NHS, and the creative life he has built beyond the hospital ward. From children's television to musical theatre, Dr Ranj reflects on chasing joy, embracing vulnerability, and why his real job - in whatever form it takes - is simply to make people feel better.Find out more about Dr Ranj's Human Body Encyclopedia hereFull Disclosure is a Global ProductionListen or watch every Friday on Global Player, YouTube or wherever you get your podcasts.EXCLUSIVE NordVPN Deal -> https://nordvpn.com/fulldisclosure Try it risk-free now with a 30-day money-back guarantee

Charlie Morley is an internationally recognized teacher of lucid dreaming, trauma-informed sleep, and mindfulness, with over 25 years of experience in lucid dreaming practice. A bestselling Hay House author, two-time TED speaker, and Mindvalley coach, Charlie has taught workshops and retreats in more than 20 countries and has worked with organizations including the NHS, the British Army, Reuters, and Oxford and Cambridge Universities. He is also the author of five books, including Wake Up to Sleep. Charlie's work bridges ancient Buddhist practices with modern science. His lucid dreaming methods have been featured in groundbreaking PTSD research, with peer-reviewed studies showing significant reductions in PTSD symptoms and nightmare distress among participants. Based in London, Charlie continues to teach, write, and train therapists while helping people use lucid dreaming to improve sleep, process trauma, and enhance emotional well-being. |SHOWNOTES:

Agne Malisauskiene joins Payman as the clinical lead at the Baltic Academy of Aesthetic Dentistry and one of the world's best-known minimally invasive composite teachers, having trained thousands of dentists from her purpose-built facility in Vilnius.She talks candidly about swapping punishing NHS-style hours in Lithuania for a much gentler introduction to UK private dentistry, and how a year at a US military boarding school as a teenager shaped the discipline and leadership instincts she still relies on today.This is also a conversation about ambition and what it costs. From the competitive streak that pushed her toward the hardest degree to get into, to the guilt and logistics of teaching abroad most weekends while raising two young boys, Agne is refreshingly honest about the trade-offs behind a career built on repetition, pattern recognition and constant travel.Expect sharp reflections on gender and ambition in dental education, why composite bonding took off early in Lithuania, and a clinical mistake that changed how she treats every tooth since.In This Episode00:00:50 – Introduction00:02:40 – Building the Vilnius teaching facility00:11:57 – Moving to the UK00:18:27 – Boarding school in America00:30:57 – Family background and choosing dentistry00:39:41 – Ambition, competitiveness and sacrifice00:46:47 – Family life and growing up in Soviet-era Lithuania00:53:12 – A typical teaching week and travel logistics01:02:32 – Joining Biomimetic01:07:33 – Gender, ambition and teaching01:15:53 – Filming through the loupe camera01:22:47 – Blackbox thinking01:26:32 – Favourite resource: Layers 201:30:27 – Fantasy dinner partyAbout Agne MalisauskieneAgne Malisauskiene is an internationally recognised minimally invasive direct composite expert and the clinical lead at the Baltic Academy of Aesthetic Dentistry in Vilnius, where she trains dentists from around the world. She is a member of Biomimetic and Enlighten's distributor in Lithuania, and splits her time between her own patients and a busy international lecturing schedule.

On this surprisingly light episode - don't worry, the EHRC stuff is coming next time - our hosts Flint and Ashleigh go over: How to clap back at Trump with some goddam class, courtesy of Dylan Mulvaney. ANOTHER study shows that HRT is effective for trans youth, this time from the Netherlands. Some notes on potential changes to the way patient data is recorded within the NHS. London Trans Pride! Our team were on the ground with around 150,000 other people, featuring interviews with author, screenwriter and actress Juno Dawson, Dee Whitnell of @s3xtheorywithdee and @transkidsdeservetogrowup and Sophie from @defundtransphobes. Unions boycotting the Labour Women's Conference for their trans-excluding policies. And for our Meat this time, we go over Andy Burnham's new cabinet picks and their past actions (or inactions) regarding trans rights.  References: https://whatthetrans.com/ep161  

This week on the Full of Beans podcast, Han is joined by Zelah Glasson. Zelah is a trans man, content creator and fitness coach who has been openly sharing his transition journey over the past two and a half years, and has lived experience of bulimia.Zelah recently made history as the first transgender man to appear on the ITV version of Big Brother, further amplifying his voice and visibility. He is now building an online personal training business focused on supporting and empowering others within his community.In this episode, we explore:Zelah's journey to personal training for trans and queer clientsZelah's bulimia recovery story and NHS eating disorder treatment gaps The difference between "In recovery" vs "recovered" How shame and control are related to bulimiaThe impact of public conversations about men's eating disordersZelah's experience of gender dysphoria, body dysmorphia and transitioningThe importance of trans representation in fitnessUsing exercise as a coping mechanism and understanding the difference between exercise and compulsive exerciseHow to build sustainable fitness habits centred on enjoyment, flexibility, and body awarenessConnect with Us:Subscribe to the Full of Beans PodcastFollow Full of Beans on InstagramCheck out our websiteListen on YouTubeConnect with Zelah via Instagram (@zelahglasson) and TikTok (@zelahglasson)⚠️ Content Note: This episode includes discussion of eating disorders (bulimia), body dysmorphia, gender dysphoria, and the relationship between exercise and disordered eating. Please take care while listening.

To have your question featured in a future video, please visit: DrMorses.TV/ask Buy herbs: https://handcraftedbotanicalformulas.... Getting Started Guide: https://handcraftedbotanicalformulas....

Is Palantir's NHS work actually doing any good? Do we need another Ali G movie? And is the AI singularity already here? Olly Mann and The Week delve behind the headlines and debate what really matters from the past seven days. With Harriet Marsden, Jamie Timson and Felicity CaponImage credit: Karwai Tang / Getty Images

The NHS became the world's first health system to commit to reaching net zero emissions in October 2020. But bold national commitments only become reality through the people doing the work at the point of care. In this Insight from Episode 104: Practicing Green Health, Emma Pascale Blakey, PhD, RN, Nurse Lead for Sustainability at NHS England, makes the case that nurses and midwives have a valuable perspective as researchers and scientists in this equation, and they are an invaluable resource when it comes to sustainability solutions. From drones delivering chemotherapy to the Isle of Wight, to health visitors cycling between family visits, to clinical procurement nurses influencing what equipment gets ordered, nurses are leading the way when it comes to sustainability.   To listen to this Insight clip's full episode, visit the SEE YOU NOW Podcast Episode 104: Practicing Green Health on APPLE, SPOTIFY, YOUTUBE, or your favorite streaming platform.   Learn more about See You Now. Visit the ANA Innovation website for additional resources. https://www.nursingworld.org/practice-policy/innovation   If you know a healthcare professional whose work reflects grit, innovation or extraordinary care—or if that story is your own—we encourage you to apply for the TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson, a branded award.   Have questions or feedback for the SEE YOU NOW team? Future episode ideas? Contact us at hello@seeyounowpodcast.com. 

After rounding up the day's main news stories, Richie is joined by Jennie Lowes.  Richie is joined by the great Jennie Lowes. Jennie is a former NHS nurse with 26 years of clinical nursing experience and six years of integrative health practice under her belt. This includes the fascinating field of classical medical astrology, something that Hippocrates famously claimed was essential to medicine itself. On today's show, Jennie discusses news that her former NHS bosses are spending hundreds of thousands of pounds per year training MEN how to breastfeed, new PM Andy Burnham's promise to reform Adult Social Care and news that Johnson and Johnson have paid a $5.5 billion dollar settlement to thousands of people who developed cancer through using talc products. Jennie also answered some terrific questions on Medical Astrology.https://www.thebarefoothealers.com/Get your own free health blueprint here:https://medicalastrologyguide.com/

Today, intense and historic wildfires continue to burn in parts of Europe with more than 300,000 people having now been evacuated across France and Spain. Adam is joined by Climate and Wildfire Scientist Theodore Keeping and Aitor Hernandez-Morales - Senior Reporter for Politico to discuss why these wildfires are so hard to control and what the political reaction to them has been. Plus, in a recent interview with Laura, Andy Burnham claimed the ‘NHS will collapse' if social care is not reformed. Henry joins Adam to unpack these comments and discuss why social care reform is so important to the new PM. You can now listen to Newscast on a smart speaker. If you want to listen, just say "Ask BBC Sounds to play Newscast”. It works on most smart speakers. You can join our Newscast online community here: https://bbc.in/newscastdiscordGet in touch with Newscast by emailing newscast@bbc.co.uk or send us a WhatsApp on +44 0330 123 9480.New episodes released every day. If you're in the UK, for more News and Current Affairs podcasts from the BBC, listen on BBC Sounds: https://bbc.in/4guXgXd Newscast brings you daily analysis of the latest political news stories from the BBC. The presenter was Adam Fleming. It was made by Jack Maclaren with Rosie Mertora and Anna Harris. The social producer was Jem Westgate. The technical producer was Rohan Madisoin. The assistant editor is Chris Gray. The senior news editor is Sam Bonham.

The investigative journalist Lucas Amin reports on how the tech company Palantir won a £330m contract with the NHS … and what happened once its software was introduced. Help support our independent journalism at theguardian.com/infocus

In episode 548 I chat with Rebecca and Dr Jeremy Rowe. Rebecca kindly agreed to share her OCD story and her therapy work with Dr Jeremy Rowe with us. Jeremy is a chartered psychologist and clinical director of Ark Psychology, a UK-based independent practice providing specialist OCD treatment, ADHD and autism assessments, psychological therapy, and coaching. With over 25 years' experience across the NHS, private practice, and the criminal justice system, Jeremy has a particular interest in Rumination-Focused ERP for OCD and integrating evidence-based approaches with a deeper understanding of the emotional and relational processes that underpin obsessive-compulsive difficulties. We discuss Rebecca's OCD story, her therapy work with Jeremy, relationship OCD (ROCD), rumination-focused exposure and response prevention therapy (RF-ERP), medication, Rebecca exploring her past in the context of her OCD, figuring out one's own OCD story, words of hope and much more. Hope it helps. Show notes: https://theocdstories.com/episode/rebecca-jeremy-548 The podcast is made possible by NOCD. NOCD offers effective, convenient therapy available in the US and outside the US. To find out more about NOCD, their therapy plans and if they currently take your insurance head over to https://go.treatmyocd.com/theocdstories Join many other listeners getting our weekly emails. Never miss a podcast episode or update: https://theocdstories.com/newsletter